Compare AbCellera Biologics Inc (ABCL) vs iShares Core Growth Allocation ETF (AOR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares Core Growth Allocation ETF — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while iShares Core Growth Allocation ETF trades at $68.51. Which is the better fit depends on your goals.
| ABCL | AOR | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $69.85 |
52-Week Low | $2.78 | $61.00 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
AOR trades at $69.28, up slightly today, with a bullish technical signal driven by moving averages. The ETF recently reached a 52-week high near $67.72 (Defense World, 2026-04-19), indicating strong momentum. Key support sits at $69, with resistance at $70. A dividend of $0.52 is scheduled for July 2026, adding income appeal.
Outlook remains positive given technical strength and recent highs, but risks include underperformance versus the S&P 500 over the long term (24/7 Wall Street, 2026-05-25). The 60/40 allocation strategy faces scrutiny, requiring monitoring of rebalancing efficacy and broader market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →
